China Biopharmaceuticals: Increasing In-Bound and Out-Bound Investments

Eric Langer, President of BioPlan Associates, joined the BPI Theater at BIO on Wednesday, 5 July 2019, to report recent movements in China’s biopharmaceutical markets. In collaboration with the Society for Industrial Microbiology (SIM) and 102 different authors from around the world, BioPlan conducted a peer-reviewed analysis of the factors driving product development in China. Results showed that market data are not the biggest factor; it is the high incidence of cancer diagnosis and death. Considering this great need and China’s expansion into biologics, the question that arises is usually: Can China evolve from “the world’s factory” offering toys, electronics, and commodities to a technologically complex environment for making and selling biologics? Langer responds that the question instead should be: How will developed regions, biomanufacturers, suppliers, regulators, and investors participate in that evolution? “Because it’s not going to slow down.”

Fill out the form below to watch the complete presentation now.

Leave a Reply